Ayala Pharmaceuticals Inc

NASDAQ:AYLA  
10.10
0.00 (-0.05%)
Earnings Announcements

Ayala Pharmaceuticals Says Existing Cash Balance To Fund Operating Expenses And Capital Expenditure Requirements Into 2023

Published: 03/25/2021 12:34 GMT
Ayala Pharmaceuticals Inc (AYLA) - Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update.
Ayala Pharmaceuticals Inc - Existing Cash Balance to Fund Operating Expenses and Capital Expenditure Requirements Into 2023.
Revenue is expected to be $1.3 Million
Adjusted EPS is expected to be -$0.71

Next Quarter Revenue Guidance is expected to be $1.3 Million
Next Quarter EPS Guidance is expected to be -$0.72

More details on our Analysts Page.